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Abstract
Background: Diabetic retinopathy (DR) is a leading cause of blindness in working age adults. Approximately 95%
of patients with Type 1 diabetes develop some degree of retinopathy within 25 years of diagnosis despite
normalization of blood glucose by insulin therapy. The goal of this study was to identify molecular changes in the
rodent retina induced by diabetes that are not normalized by insulin replacement and restoration of euglycemia.
Methods: The retina transcriptome (22,523 genes and transcript variants) was examined after three months of
streptozotocin-induced diabetes in male Sprague Dawley rats with and without insulin replacement for the later
one and a half months of diabetes. Selected gene expression changes were confirmed by qPCR, and also
examined in independent control and diabetic rats at a one month time-point.
Results: Transcriptomic alterations in response to diabetes (1376 probes) were clustered according to insulin
responsiveness. More than half (57%) of diabetes-induced mRNA changes (789 probes) observed at three months
were fully normalized to control levels with insulin therapy, while 37% of probes (514) were only partially
normalized. A small set of genes (5%, 65 probes) was significantly dysregulated in the insulin-treated diabetic rats.
qPCR confirmation of findings and examination of a one month time point allowed genes to be further
categorized as prevented or rescued with insulin therapy. A subset of genes (Ccr5, Jak3, Litaf) was confirmed at the
level of protein expression, with protein levels recapitulating changes in mRNA expression.
Conclusions: These results provide the first genome-wide examination of the effects of insulin therapy on retinal
gene expression changes with diabetes. While insulin clearly normalizes the majority of genes dysregulated in
response to diabetes, a number of genes related to inflammatory processes, microvascular integrity, and neuronal
function are still altered in expression in euglycemic diabetic rats. Gene expression changes not rescued or
prevented by insulin treatment may be critical to the pathogenesis of diabetic retinopathy, as it occurs in diabetic
patients receiving insulin replacement, and are prototypical of metabolic memory.
Background
Impairment or loss of vision due to diabetic retinopathy
(DR) is one of the most debilitating complications of dia-
betes. Type 1 diabetes leads to some degree of diabetic
retinopathy (DR) in approximately 95% of patients within
20 years of diagnosis [1,2], and the incidence of DR con-
t i n u e st oi n c r e a s ed u et ot h ed r a m a t i cr i s ei nt h e
prevalence of Type 2 diabetes. Prevention by glycemic
control through insulin replacement [3] and ablative laser
surgery for advanced disease continue to be the standard
of care. Currently there are no approved pharmacothera-
peutic approaches for prevention and/or reversal of DR.
The Diabetic Control and Complications Trial
(DCCT) demonstrated a significant reduction, but not
elimination, of the development of diabetic complica-
tions in Type 1 diabetics through intensive insulin ther-
apy as opposed to conventional insulin therapy [3]. The
continuation study, Epidemiology of Diabetic
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patients formerly on conventional insulin therapy retained
a higher risk for development of complications, including
DR, even four [4] and ten [5] years after switching to
intensive insulin therapy despite achieving equivalent gly-
cosylated hemoglobin (HbA1c levels). This clinical phe-
nomenon is also apparent with Type 2 diabetics as
demonstrated by the United Kingdom Prospective Dia-
betes Study (UKPDS) where a “sustained legacy” of micro-
vascular complication development was evident in the
conventional treatment group despite being under inten-
sive treatment recommendations for the past ten years [6].
As many Type I and II diabetes patients experience signifi-
cant glycemic insults prior to diagnosis and/or do not
achieve tight blood glucose control for a period of time
after diagnosis, these studies suggest that these patients
will be at a higher risk for complications development in
the future even under intensive insulin therapy.
Animal models of diabetes demonstrate a similar phe-
nomenon of DR development even with insulin therapy as
the longitudinal clinical studies. Twenty years ago, retino-
pathy, as measured by retinal capillary aneurysms and
lesions, was observed in dogs after 4.5 years of diabetes,
despite good glycemic control for the last 2.5 years [7]. In
rodent models of diabetes, islet cell transplantation after 6
weeks of diabetes, but not after 12 weeks of diabetes,
reduced the development of DR when both groups were
examined at 26 total weeks of diabetes [8]. A number of
additional studies have examined this phenomenon at the
level of retinal expression of specific genes and proteins in
rodent models [9-11]. For example, in a Lewis rat STZ
model, increased retinal expression of IL-1B, TNFa,
ICAM-1 and iNOS with diabetes has been demonstrated
to be prevented by good glycemic control, but once estab-
lished can not be reversed by long-term insulin therapy
[9]. In total, the clinical and basic research literature
clearly supports the hypothesis that some retinal molecu-
lar alterations induced during a period of poor or no con-
trol cannot be reversed by subsequent good glycemic
control and that other molecular alterations are not pre-
vented from developing after initiation of insulin replace-
ment. This phenomenon has been termed ‘metabolic
memory’ [12]. The mechanisms through which metabolic
memory is retained and the role of metabolic memory in
DR disease development remain to be described [13]. The
present study sought to address this hypothesis of persis-
tent dysregulation of gene expression for the first time
with whole genome analysis of retinal transcriptome with
untreated diabetes and with insulin therapy.
Methods
Animal Methods
Animal studies were conducted using protocols
approved by the Penn State Institutional Animal Care
and Use Committee. Male Sprague-Dawley rats (Charles
River, Wilmington, MA) were imported at 100-125 g
body weights. After one week, rats were fasted overnight
and diabetes was induced by intraperitoneal injection of
65 mg/kg streptozotocin (STZ; Sigma Aldrich, St. Louis,
M O )i n1 0m Ms o d i u mc i t r a t ev e h i c l e ,p H4 . 5a sp r e -
viously described [14-16]. Control rats received the
same treatment, but were injected with an equal dose of
vehicle only. Throughout the study, rats were main-
tained on a 12 hour light/dark cycle and had free access
to food and water. To confirm induction of diabetes,
blood glucose and body weight of all animals were
assessed one week post-injection, and then biweekly
throughout the study. Only STZ-injected rats with
blood glucose levels >250 mg/dL at initial and subse-
quent testing were included in the diabetic groups.
Rats in the insulin treatment group received one 26
mg subcutaneous insulin pellet (LinShin Canada, Scar-
borough, Canada) delivered via trocar six weeks after
induction of diabetes. An additional 26 mg implant was
introduced when midday non-fasting blood glucose
exceeded 250 mg/dL or when body weight exceeded 300
g. Control and untreated diabetic rats were treated simi-
larly but received no insulin implants. Retinas for the
insulin-treatment experiment (insulin-treated diabetic,
untreated diabetic, and age-matched non-diabetic con-
trols) were harvested at three months post-injection. A
second set of rats (control and untreated diabetic groups
only) were sacrificed one month after injection for use
in the qPCR experiments.
At sacrifice, body weights were recorded and blood
glucose concentrations and percent glycosylated hemo-
globin were measured from tail-nick blood samples
using a Lifescan glucose meter and Siemens DCA analy-
zer, respectively. Rats received a lethal 100 mg/kg dose
of pentobarbital (Nembutal; Ovation Pharmaceuticals
Inc., Deerfield, IL) by intraperitoneal injection. Corneas
were hemisected and the lens and vitreous were
removed. Whole retinas, including RPE, were rapidly
excised with fine forceps and snap-frozen in liquid
nitrogen for subsequent transcriptomic analysis.
Throughout the study, all rats were maintained by the
Penn State JDRF Animal Models Core in accordance
with the Institutional Animal Care and Use Committee
guidelines under specific pathogen-free conditions and
monitored by quarterly sentinel testing.
RNA isolation
Retinas were homogenized in 500 μL TriReagent (Mole-
cular Research Center, Cincinnati, OH) by bead mill
(Retsch TissueLyzer II, Qiagen, Valencia, CA) using 3
mm stainless steel balls at 30 Hz for 30 seconds, as pre-
viously described [14,16]. RNA was isolated from retinal
homogenates using standard TriReagent/BCP disruption
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by incubation with isopropanol at -20°C, RNA was puri-
fied using the Qiagen RNeasy Mini kit (Qiagen). Quan-
tity and quality assessments were made by spectrometry
(NanoDrop ND1000; Thermo Scientific, Wilmington,
DE) and microfluidics chip (Agilent 2100 Expert Bioana-
lyzer Nano Chip, Agilent, Palo Alto, CA), respectively.
Only samples with RNA integrity numbers >8 were used
in analyses.
Microarray analysis
Retinal transcriptomic analysis of insulin-treated dia-
betic, untreated diabetic, and age-matched non-diabetic
rats (n = 8/group, three-month experiment) was per-
formed using Illumina RatRef-12 microarray (Illumina,
San Diego, CA) according to standard methods and as
previously described [17,18]. First-strand cDNA was
synthesized by reverse transcription from 500 ng input
RNA by two-hour incubation at 42°C with T7 Oligo(dT)
primer, 10 × First Strand buffer, dNTPs, RNase inhibi-
tor, and ArrayScript. Second-strand cDNA was synthe-
sized from first-strand cDNA by two hour incubation at
16°C with 10 × Second Strand buffer, dNTPs, DNA
polymerase, and RNase H, purified using the Illumina
TotalPrep kit (Ambion, Foster City, CA) according to
manufacturer’s protocols and eluted in 18 μL5 5 ° C
nuclease-free water. cRNA was synthesized from sec-
ond-strand cDNA using the MEGAscript kit (Ambion),
and labelled by incubation for 14 hours at 37°C with T7
10 × Reaction buffer, T7 Enzyme mix, and Biotin-NTP
mix. Following purification with the Illumina TotalPrep
RNA Amplification kit (Ambion) according to manufac-
turer’s instructions, cRNA yields were quantitated using
a NanoDrop ND1000 spectrometer. Biotinylated cRNA
(750 ng) was hybridized to RatRef-12 BeadChips by
incubating for 20 hours at 58°C at a rocker speed of 5.
After incubation, BeadChips were washed and streptavi-
din-Cy3 stained, dried by centrifugation at 275 × g for 4
minutes and scanned and digitized using a Bead Station
Bead Array Reader.
After initial quality control of arrays, three arrays from
the diabetic group and one from the insulin-treated dia-
betic group were eliminated for high background, low
wash stringency or due to large blemishes on the array.
Average normalization with background subtraction was
performed in GenomeStudio software (Illumina) and flat
files were imported into GeneSpring GX11 (Agilent)
software for data analysis. Using detection p-values gen-
erated by GenomeStudio, probes were filtered for only
those with present or marginal calls in 100% of the sam-
ples in at least one of the three experimental groups.
This ensured that 1) transcripts not reliably detected in
the experiment were excluded from statistical analysis,
and 2) that genes potentially expressed in only one
experimental animal group (i.e., in non-diabetic, dia-
betic, or insulin-treated diabetic rats only) were retained.
Differential gene expression was determined using a
combination of pair-wise statistical p-value (t-test, P <
0.05) and |fold-change| cutoff >1.2 fold between non-
diabetic and diabetic groups according to standards in
the field [19] and as previously described [17,18]. All of
the genes differentially expressed between the non-dia-
betic and diabetic groups were then further classified by
the expression in the insulin-treated diabetic group.
Genes significantly altered with diabetes were classified
as not normalized, partially normalized, normalized, or
inverted by insulin replacement. The full microarray
dataset is available in the Gene Expression Omnibus,
accession# GSE24423. Network analysis of differentially-
e x p r e s s e dg e n e sn o tn o r m a l i z e dw i t hi n s u l i nt r e a t m e n t
was performed using Ingenuity Pathway Analysis soft-
ware (Ingenuity Systems, Redwood City, CA) to identify
potential networks/pathways of interest among these
genes. Gene Set Analysis [20] was performed using
GeneSpring GX with minimum set size of 10 and a p-
value of <0.05, and Benjamini Hochberg false discovery
rate (FDR) correction. Comparison gene sets were
downloaded from MSigDB (Broad Institute) for Gene
Ontology (c5, 1454 gene sets) and motif gene sets (c3,
836 gene sets).
Quantitative RT-PCR
qPCR analysis of targets of interest was performed as
previously described, using TaqMan Assay-On-Demand
(Applied Biosystems, Foster City, CA) gene-specific pri-
mers and probes and a 7900 HT Sequence Detection
System (Applied Biosystems) [14,16]. Both one month
(non-diabetic and diabetic) and three month (non-dia-
betic, diabetic, and insulin-treated diabetic) were ana-
lyzed by qPCR. Relative gene expression was calculated
with SDS 2.2.2 software using the 2
-ΔΔCt analysis
method with b-actin as an endogenous control. b-actin
expression was determined to be unchanged between
animal groups in a preliminary absolute quantitation
experiment (data not shown). For a full list of primer/
probe sets, see Additional File 1. Based on the qPCR
results, genes were subdivided into “rescue” and “pre-
vention” categories depending on whether a significant
change in transcript was or was not evident at the one
month time point, respectively.
Immunoblot analysis
Soluble protein was isolated from retinas contralateral to
those used in the three month qPCR analysis by homo-
genization in 250 μL detergent-based protein lysis buffer
(2.5 mM HEPES, 1 mM EDTA, 100 mM NaCl, 1 mM
dithiothreitol, 1% Tween 20, 1 mM Na3VO4,2p r o t e a s e
inhibitor tablets/15 mL). Insoluble material was removed
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Protein concentrations were determined by Pierce BCA
assay. Protein samples (20 μg) were separated on Criter-
ion 4-20% gradient gels (Bio-Rad, Hercules, CA) and
transferred to PVDF membranes (GE Healthcare). Mem-
branes were incubated with primary antibodies [CCR-5
(sc-17833), Jak3 (sc-6932), and Litaf (sc-166719) from
Santa Cruz Biotechnology, Santa Cruz, CA] and HRP-
conjugated anti-mouse IgG (ThermoFisher Scientific,
Waltham, MA), anti-mouse IgA (Santa Cruz Biotechnol-
ogy), or anti-rabbit IgG (GE Healthcare) secondary anti-
bodies. Blots were developed on film (ThermoFisher
Scientific) using enhanced chemiluminescence (Pierce,
Rockville, IL) and images were analyzed by digital densi-
tometry using ImageQuant TL software (GE Health-
care). Resultant immunoblot data was standardized to
the corresponding whole-lane densitometric volume of
the total protein stained gel as described previously [21].
Statistical Analysis
Microarray data were filtered and analyzed as described
above. For all qPCR experiments, the data for individual
samples were normalized to the corresponding b-actin
signal. Statistical analyses were performed using Sigma-
Stat 3.5 software, with two-tailed t-tests for pairwise
comparisons (i.e., one-month diabetic vs. non-diabetic)
and one-way ANOVA with Student Newman Keuls
post-hoc tests for multiple group comparisons (i.e.,
three-month diabetic vs. insulin-treated diabetic vs. non-
diabetic). Statistical significance was determined by P <
0.05. Pearson correlations between gene expression
levels and blood glucose or percent glycosylated HbA1c
utilized a P < 0.05 to determine significance.
Results
Animal Results
At sacrifice, diabetic rats were hyperglycemic compared
to both non-diabetic rats and insulin-treated diabetic
rats (Figure 1A). No differences at sacrifice in blood glu-
cose were observed between non-diabetic and insulin-
treated diabetic rats. Glycosylated hemoglobin levels
were also elevated in diabetic rats (Figure 1B). Insulin-
treated diabetic rats had significantly lower levels of gly-
cosylated hemoglobin compared to diabetic rats but
slightly elevated levels compared to non-diabetic rats.
Rats in the diabetic group were underweight as com-
pared to both non-diabetic and insulin-treated diabetic
groups (Figure 1C). The mean weights of the insulin-
treated diabetic rats were also less than those of the
non-diabetic group.
At the one month timepoint used in the qPCR confir-
mation experiments, diabetic rats had significantly ele-
vated blood glucose at sacrifice (321 ± 16 diabetic, 114
± 12 non-diabetic, P < 0.001, t-test). The one month-
diabetic rats were also underweight compared to non-
diabetic controls (264 ± 16 diabetic, 391 ± 9 non-dia-
betic, P < 0.001). Glycosylated hemoglobin levels were
not measured in the one month experiment.
Transcriptome Profiling Results
11,040 probes, out of the 22,523 probes on the arrays,
passed the criteria for detectable expression. A total of
1,376 probes were determined to be differentially
expressed between the non-diabetic and diabetic groups
(P < 0.02, |fold change| >1.2). Probes differentially
expressed between non-diabetic and diabetic groups
were then clustered into Not Normalized, Partially Nor-
malized, Normalized, and Inverted expression groups
based on whether there was a significant difference in
expression between non-diabetic and insulin-treated dia-
betic groups (Figure 2). Not Normalized probes (65,
Additional file 2) were those for which there was a sig-
nificant difference in the same direction between the
non-diabetic group and both the diabetic and insulin-
treated diabetic groups. Partially Normalized probes
(514, Additional file 3) were those with a statistically sig-
nificant change between the non-diabetic and diabetic
groups that was sufficiently normalized for there to be
no significant difference between the non-diabetic and
insulin-treated diabetic comparison but not normalized
to an extent where there was a significant difference
between untreated diabetic and insulin-treated diabetic
groups. Normalized probes (789, Additional file 4) were
significantly regulated in the non-diabetic versus diabetic
comparison and the diabetic versus insulin-treated dia-
betic comparison. A small number of probes (8,
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Figure 1 Biometric data for experimental groups.A ts a c r i f i c e ,
blood glucose levels (A) were significantly higher in the diabetic
rats than the control and insulin-treated groups. Similarly,
glycosylated hemoglobin levels (B) were elevated in diabetic rats as
compared to controls and insulin-treated diabetic rats. Diabetic rats
were also underweight (C) as compared to controls and insulin-
treated diabetic groups. One-way ANOVA, Student Newman Keuls
pair-wise post-hoc test, **P < 0.01, ***P < 0.001, n = 7-10/group.
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Page 4 of 14Additional file 5) displayed an Inverted profile in which
the induction or reduction in the non-diabetic versus
diabetic comparison flipped to a significant reduction or
induction in the non-diabetic versus insulin-treated dia-
betic comparison.
Analysis of gene networks extends the finding of sets of
genes with differential patterns of expression in response
to insulin therapy. For example, an inflammation related
network of diabetes changes with nodes of Vegf, Pdgf,
and NFkB was evident in the comparison of diabetics to
non-diabetic controls (Figure 3A). This network was
insensitive to insulin therapy (i.e., Not Normalized) (Fig-
ure 3B). In, contrast, a transcriptional network centred
on Myc and altered in diabetic animals as compared to
non-diabetic controls was almost completely normalized
by insulin treatment (Additional File 6).
Gene Set Analysis was performed on all categories of
changes, except for Inverted, for gene ontology and reg-
ulatory motif over-representation. AP2 binding sites and
a CACCC motif with no known binding factor were
enriched in the set of all changes with diabetes (P <
0.05, minimum of 5 genes). Gene Set Analysis of the
Normalized subgroup identified Myc regulated genes as
enriched, confirming the network analysis above. In the
Partially Normalized subgrouping, a set of genes with
the predicted mir-330 binding target (TGCTTTG) was
over-represented, all of which were suppressed in dia-
betic and insulin-treated diabetic compared to non-dia-
betic controls. No enriched gene sets were found in the
Not Normalized group.
Previously, we have examined whole-retina transcrip-
tional changes in the same rat model after three months
of diabetes using Illumina RatRef12 microarrays but
with fewer samples per group (n = 4) and no insulin-
treated diabetic group [18]. Comparison of the current
dataset with the previous study identified 277 genes sig-
nificantly regulated in the same manner as observed
previously. Of the 27 genes selected for qPCR analysis
23 were observed in this previous study to be differen-
tially regulated with diabetes in the microarray data. We
have also previously reported a set of 14 retinal mRNA
biomarkers for use in preclinical DR drug development
studies [16]. Eleven of the 14 genes in the biomarker
panel were identified as significantly regulated with dia-
betes in the current microarray analysis. The consistency
of these expression changes across multiple independent
studies suggests a robust and reproducible gene expres-
sion response in this model.
Extending these comparative analyses we examined
the 77 transcripts previously reported by Gerhardinger
and colleagues as differentially expressed in Müller cells
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Figure 2 Microarray analysis. Retinal RNA from control (n = 8),
diabetic (n = 5) and insulin-treated diabetic (n = 7) rats collected
after the 3 months experimental paradigm were analyzed by
Illumina Rat Ref12 microarray. 11,040 of 22,523 probes on the
microarray had detectable signals. The 1,376 probes determined to
be differentially expressed (P < 0.05, |fold change| >1.2) between
control and diabetic animals were clustered according to expression
in the insulin-treated diabetic group into Not Normalized, Partially
Normalized, Normalized, and Inverted expression groups.
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induction of diabetes by STZ injection [18]. Of the 63
genes that could be confidently cross-matched (based
on Entrez Gene IDs) 17 were also significantly changed
between non-diabetic and diabetic groups in this study.
Importantly, all of these changes were in the same direc-
tion (up- or down-regulation) as the previous report.
While the previous report specifically examined Müller
cells isolated after 6 months of diabetes, the common
changes suggest that the microarray analysis performed
in this study of whole retinal tissue is able to detect
changes occurring in the Müller cell population.
Confirmation qPCR Results
An important element in characterizing retinal transcrip-
tomic changes with diabetes that are unresponsive to insu-
lin treatment is determining when these diabetes-induced
changes first occur. In other words, do these changes
occur before initiation of insulin treatment or after initia-
tion of insulin treatment? To answer this question, specific
target mRNAs from the whole genome gene expression
analysis were also examined in separate non-diabetic and
diabetic rat groups sacrificed one month after vehicle or
STZ injection. Analysis of the data from the three month
insulin intervention experiment in the context of this one
month duration of diabetes experiment (i.e., prior to initia-
tion of insulin treatment) permits further refinement of
gene expression patterns into more specific Rescued and
Prevented categories. Rescued, Partially Rescued, and Not
Rescued are those gene expression changes which are
manifest after one month of diabetes, before initiation of
insulin treatment, and are normalized, partially normal-
ized, or not normalized with chronic insulin treatment,
respectively. Prevented, Partially Prevented, and Not Pre-
vented groupings are those changes which have not
occurred at one month of diabetes and do not occur by
three months if insulin treatment is begun, occur by three
months of diabetes at a significantly lesser magnitude with
insulin treatment, or occur by three months of diabetes
regardless of insulin treatment.
A total of 27 targets from the microarray analysis were
chosen for confirmation analysis including 15 from the
Not Normalized, 5 from the Partially Normalized and 7
from the Normalized groups. While not comprehensive
of all the genes observed with differential expression in
the microarray analysis, the extensive qPCR confirma-
tion experiments validate the quantitative accuracy of
the discovery experiments. Twenty six of the 27 (96%)
genes examined in this analysis were confirmed as being
differentially regulated with diabetes in a statistically sig-
nificant manner at the three month time-point
(ANOVA, SNK post-hoc, P < 0.05). Eight of the 26
genes tested by qPCR were found to be differentially
regulated after one month of diabetes. Using the qPCR
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Figure 3 Network analysis of genes Not Normalized. Genes and
expression values from the Not Normalized category were
examined for networks of interrelated genes using Ingenuity
Pathway Analysis software. One significant network was centered
around Pdgf, Nfkb, and Jnk. Expression values for the control versus
diabetic groups is presented in A and for the insulin-treated
diabetic versus diabetic comparison in B. Relationships are
presented as lines and arrows. Red lines represent activation or
positive regulation of expression while green lines indicate
inhibition or negative regulation of expression. Grey lines are known
protein-protein interactions and dashed lines are indirect
relationships. Gene symbols are coded as green for significantly
reduced expression, red for significantly reduced expression, and
white for no change in expression.
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categories. Five were Not Rescued (Figure 4) and three
were Rescued (Figure 5), with the remainder of genes
dividing into four Not Prevented (Figure 6), four Par-
tially Prevented (Figure 7), and 10 Prevented (Figure 8).
To assess whether the continued dysregulation of
genes in the Not Rescued, Not Prevented and Partially
Prevented gene categories was due to insufficient or
unstable metabolic control, glycosylated hemoglobin
levels at sacrifice were examined for correlation to
gene expression in the insulin-treated diabetic animals.
In the Not Prevented and Partially Prevented cate-
gories, only A2m, Ccr5, and Jak3 gene expression was
significantly correlated to %HbA1c (Pearson correla-
tion, P < 0.05), suggesting these genes may be respon-
sive to small increases in %HbA1c such as those
observed in the insulin-treated diabetic animals. None
of the Not Rescued genes were correlated to the level
of glycosylated hemoglobin in the insulin-treated dia-
betic animals, suggesting that these persistent changes
a r en o tr e l a t e dt ob l o o dg l u c o s eo r% H b A 1 cl e v e l si n
the time period immediately prior to sacrifice. How-
ever, other metabolic disturbances such as AGE-RAGE
may account for the continuing dysregulation of these
genes.
Protein Expression Results
While targeted analysis of the protein expression of
every gene examined in this study is not feasible,
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Figure 4 Transcript expression not rescued by insulin
treatment. qPCR confirmation experiments also included 1 month
control and diabetic groups to determine if retinal mRNA
expression changes occurred before initiation of insulin treatment.
Lad1, Litaf1, Mt1a, and Txnip all demonstrated a ‘not rescued’
molecular phenotype of increased expression in diabetic animals at
1 month of diabetes which remained elevated at 3 months in
diabetic and insulin-treated diabetic groups. Similarly, Rgr expression
was decreased at one month of diabetes and remained depressed
at three months in diabetic animals with and without insulin
treatment. One-way ANOVA, Student Newman Keuls pair-wise post-
hoc test, *P < 0.05, **P < 0.01, ***P < 0.001 for 3 month data; t-test
#P < 0.05, ##P < 0.01, ###P < 0.001 for 1 month data; n = 7-11/
group for both time points. ND - Non-Diabetic control, D - Diabetic,
D+I - Insulin-treated Diabetic, 1M - 1 month, 3M - 3 Months.
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Figure 5 Transcript expression rescued by insulin treatment.
Several transcripts were also confirmed by qPCR to demonstrate a
‘rescued’ phenotype. For these transcripts the altered mRNA
expression in diabetic animals at one month was still observed in
diabetic animals at three months but insulin-treatment normalized
the expression. The decreased expression Dcps, Kcne2, and Nppa
was brought to equivalent expression levels as controls at the three
month timepoint by insulin treatment. One-way ANOVA, Student
Newman Keuls pair-wise post-hoc test, *P < 0.05, **P < 0.01, ***P <
0.001 for 3 month data; t-test #P < 0.05, ##P < 0.01, ###P < 0.001
for 1 month data; n = 7-11/group for both time points. ND - Non-
Diabetic control, D - Diabetic, D+I - Insulin-treated Diabetic, 1 M - 1
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Page 7 of 14confirmation that some of these changes in mRNA
expression are reflected in altered protein expression is
critical to the functional relevance of these alterations.
Ccr5, Jak3, and Litaf protein expression was examined
in the same three month animal cohort as the qPCR
analysis, and was found to be significantly elevated in
diabetic and insulin-treated diabetic groups compared to
non-diabetic controls (Figure 9).
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Figure 6 Transcript dysregulation not prevented by insulin
treatment. In qPCR confirmation experiments, a set of genes was
observed which were unaltered in expression after one month of
diabetes but were differentially expressed at in both diabetic and
insulin-treated diabetic groups at three months. This ‘not prevented’
phenotype was evident in the increased expression of Ccr5, Jak3,
Qprt, and Ssh3 genes. One-way ANOVA, Student Newman Keuls
pair-wise post-hoc test, *P < 0.05, **P < 0.01, ***P < 0.001 for 3
month data; n = 7-11/group. ND - Non-Diabetic control, D -
Diabetic, D+I - Insulin-treated Diabetic, 1 M - 1 month, 3 M - 3
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Figure 7 Transcript dysregulation partially prevented by
insulin treatment. A set of gene in the qPCR experiments
presented a ‘partially prevented’ phenotype in which gene
expression changes in diabetic animals were significantly
ameliorated by insulin treatment but altered expression from
control animals was still evident. Increased expression of A2 m,
Fabp7, and Gfap was reduced by insulin treatment but was still
significantly higher than in the control group. Similarly, Npr3
expression in the insulin-treated diabetic rats was not significantly
different from that in control rats, nor was it significantly different
from the diabetic rats. One-way ANOVA, Student Newman Keuls
pair-wise post-hoc test, *P < 0.05, ***P < 0.001 for 3 month data; n
= 7-11/group. ND - Non-Diabetic control, D - Diabetic, D+I - Insulin-
treated Diabetic, 1 M - 1 month, 3 M - 3 Months.
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As DR occurs in Type I diabetes patients in spite of
insulin therapy, this study sought to characterize the
limitations of insulin replacement in normalizing dia-
betes-induced molecular changes in the retina by identi-
fying gene expression alterations resistant to
normalization by chronic insulin therapy. The use of a
Type I diabetes animal model allows for the examina-
tion of retinal gene expression with and without insulin
treatment and at different durations of diabetes in a
manner not possible in humans.
Gene expression alterations normalized with insulin
treatment
As observed in the microarray analysis, the majority of
diabetes-induced changes were normalized with insulin
treatment. In confirmatory qPCR experiments that also
examined a one month duration of diabetes, some of
these normalized genes were further subdivided into
“rescued” and “prevented” categories. The expression
patterns of Kcne2, Nppa, and Dcps provide examples of
how restoration of insulin and euglycemia can normalize
diabetes-induced gene expression alterations that have
occurred before initiation of therapy to non-diabetic
levels. Additionally, a number of changes not evident at
the one month time point were prevented from occur-
ring with continued diabetes by insulin therapy. The
majority of these genes examined in the confirmation
experiments (i.e., Car13, Carhsbp1, Chi311, Timp1,
C1inh, C1s, Hspb1, Icam1, Lgals3) are proinflammatory
signalling molecules and have been described elsewhere
[14,16,18,22,23]. These data provide clear evidence that
animal model testing of novel DR treatments should be
performed in the context of insulin replacement to
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Figure 8 Transcript dysregulation prevented by insulin treatment. Genes which were confirmed in qPCR experiments to not be
differentially expressed at one month but differentially expressed at three months in the diabetic but not the insulin-treated diabetic were
classified as ‘Prevented’. Increased expression of C1s, C1Inh, Carhspb1, Chi3L1, Hspb1, Icam1, Lgals3, and Timp1 was observed but completely
prevented by one and a half months of insulin treatment. Similarly, decreased expression of Car14 and Drd5, was observed and prevented by
insulin treatment. One-way ANOVA, Student Newman Keuls pair-wise post-hoc test, *P < 0.05, **P < 0.01, ***P < 0.001 for 3 month data; n = 7-
11/group. ND - Non-Diabetic control, D - Diabetic, D+I - Insulin-treated Diabetic, 1 M - 1 month, 3 M - 3 Months.
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Page 9 of 14more closely mimic the clinical scenario and assess the
combinatorial effects of any potential therapies, as insu-
lin therapy alone is insufficient to fully restore the nor-
mal retinal transcriptomic phenotype.
Gene expression alterations not rescued by insulin
therapy
In this study we identified a number of gene expression
changes evident at 1 month of diabetes that were not
reversed by chronic insulin therapy. The basement
membrane anchoring filament protein Lad1 contributes
to epithelial stability [24] and is regulated by both gluco-
corticoid receptor activation [25] and LPS stimulation
[26]. Similarly, Mt1a is expressed in vascular compo-
nents of the blood-retina barrier [27] and is regulated
by pro-inflammatory signalling molecules, including fac-
tors released by Müller glia [28]. The regulation of these
vascular function genes indicates a potential mechanism
through which inflammation may contribute to vascular
abnormalities in the diabetic retina. Several other
inflammatory response genes induced with diabetes
were also not rescued by insulin treatment. Litaf1, an
inducer of TNFa expression [29], is a pro-inflammatory
modulator induced in monocytes and macrophages in
response to inflammatory stimuli such as LPS [30].
Txnip inhibits the antioxidant molecule thioredoxin,
increases proinflammatory gene expression and signal-
ling cascades [31]. Inhibition of Txnip in retinal
endothelial cells prevents pathologies associated with
early diabetic retinopathy (i.e., inflammation and gliosis)
[32]. The induction of Lad1, Litaf1, Mt1a, and Txnip in
the retina after 1 month of diabetes and the continued
induction of these transcripts at three months of dia-
betes despite insulin replacement for the past 1.5
months suggest persistent alterations in glial and inflam-
matory processes, even with normalization of blood
glucose levels. Rgr, a G protein-coupled receptor
expressed almost exclusively in the retina [33] and loca-
lized to Müller glia and the retinal pigment epithelium
[34], encodes a photoisomerase that contributes to pig-
ment regeneration in photoreceptors. In Rgr-/- mice,
dark adaptation is delayed and attenuated [35], suggest-
ing that the suppression of Rgr observed could play a
role in the well described deficits in dark adaptation in
early DR. The expression pattern of these genes is con-
sistent with the metabolic memory phenotype and
demonstrates that even a one month period of loss of
insulin signalling and hyperglycemia can result in mole-
cular alterations that are unresponsive to insulin treat-
ment. Recent work suggests that these metabolic
memory prototypical changes may be regulated through
epigenetic mechanisms [36,37].
Diabetes-induced gene expression changes not prevented
by insulin treatment
In addition to the gene expression changes at one
month of diabetes Not Rescued by insulin treatment,
the gene expression alterations identified in this study
Not Prevented by insulin replacement and re-establish-
ment of euglycemia are of importance for understanding
DR in the context of insulin therapy and identifying tar-
gets for adjuvant therapies. The Not Prevented pheno-
type genes were expressed at non-diabetic control levels
at one month of diabetes, but became significantly dys-
regulated with a longer duration (three months) of dia-
betes regardless of insulin treatment for the last one and
a half months. Several proinflammatory genes exhibited
this expression pattern. Ccr5, which mediates leukocyte
attraction via chemokine receptor signalling, plays well
characterized roles in inflammation [38]. In Type 1 and
2 diabetic patients, plasma Ccr5 is elevated and corre-
lates to % glycosylated HbA1c levels [39,40]. We
observed a similar positive correlation of CCR5 gene
expression to glycosylated hemoglobin levels. Jak3, a
proinflammatory gene expressed by immune cells and
activated by interleukin receptors, is regulated by
inflammation and tissue damage in the retina [41] in
models of photic damage and retinal degeneration. We
have previously reported the upregulation of Jak3 at
three months of untreated diabetes in the STZ rat
model [14,16] and the failure of insulin to prevent upre-
gulation of Jak3 suggests that insulin therapy is insuffi-
cient to prevent some aspects of retinal inflammation
with diabetes. Increased Qprt expression is also asso-
ciated with tissue damage and neurodegeneration [42].
The protein product of this gene catalyzes the break-
down of neurotoxic quinolinate in the tryptophan nico-
tinamide adenine dinucleotide pathway, preventing the
intracellular accumula tion of toxic compounds and
maintaining neuronal function. By regulating actin/
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Figure 9 Protein expression not normalized by insulin
treatment. Increased expression of Ccr5, Jak3, and Litaf1 was
confirmed by immunoblotting. One-way ANOVA, Student Newman
Keuls pair-wise post-hoc test, *P < 0.05, **P < 0.01, ***P < 0.001 for
3 month data; n = 5-7/group. ND - Non-Diabetic control, D -
Diabetic, D+I - Insulin-treated Diabetic, 1 M - 1 month, 3 M - 3
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Page 10 of 14cofilin dynamics necessary for cytoskeletal plasticity,
Ssh3 influences neuronal function and has been loca-
lized to the inner retinal layer in the eye [43], suggesting
a role in ganglion cell function.
In addition to these gene expression changes, several
others were only partially prevented by insulin therapy.
A2m, a cytokine transporter induced by interleukin
and predominantly expressed in blood vessel walls and
the retinal pigment epithelium in the retina has also
been described as systemically elevated in diabetes
patients [44]. In retina of diabetic rodents, A2m
expression increases in astrocytes and the inner limit-
ing membrane, suggesting a broad inflammatory insult
to both the neural and vascular retina [45]. Increased
Gfap, a hallmark of gliosis, also increases with inflam-
mation and diabetes [46-48]. This gene is expressed by
astrocytes and Müller glia throughout the retina and
likely contributes to inflammatory cascades and neuro-
vascular dysfunction in diabetic retinopathy. Npr3,
contributes to vascular regulation of electrolyte con-
centrations and fluid balance [49,50]. The failure of
insulin to prevent dysregulated Npr3 expression may
lead to an abnormal extracellular environment in the
retina that has the potential to induce inflammation
and neuronal dysfunction.
Together, the findings of this study demonstrate the
ability of chronic insulin therapy, initiated after one and
a half months of uncontrolled diabetes, to normalize the
majority of retinal gene expression changes. However,
chronic insulin therapy fails to completely restore the
retinal transcriptome to a non-diabetic control pheno-
type. Additionally, at least some of these transcript
changes are reflected in altered abundance of the corre-
sponding proteins. Given the well supported hypothesis
that a feed-forward cycle of inflammation and neurovas-
cular dysfunction is a causative factor in DR develop-
ment [51,52], it is not surprising that the majority of
genes dysregulated with diabetes and not normalized by
insulin are implicated in inflammatory responses and
neuronal and vascular function. As such, these changes
may represent the first stages of this feed forward cycle.
Some previously reported pro-inflammatory molecules
(e.g, IL-1b and TNFa) were not detectable, suggesting a
low level of mRNA expression. Recent reports have
emphasized the dependence of the duration of hypergly-
cemia on the induction of these factors [53]. Future stu-
dies will need to assess whether the observed induction
of pro-inflammatory factors, such as Ccr5, Litaf, Txnip,
and Jak3, result in further activation of prototypical
inflammatory signals at a later time.
These results also agree with the clinical findings of
past hyperglycemic periods continuing to confer an
increased the risk of DR and other diabetic complica-
tions long after restoration of euglycemia [5]. Additional
studies are needed to examine other complications for
similar molecular profiles. This ability of insulin to nor-
malize much, but not all, of the non-diabetic control
transcriptomic phenotype may attenuate or delay the
development of DR pathology, but ultimately the contin-
ued dysregulation of neuronal, vascular, and inflamma-
tion related genes may lead to more classical aspects DR
development such as edema, leukostasis, and neuronal
apoptosis.
The regulatory mechanisms underlying the retinal
gene expression changes observed in this study remain
to be determined. The nearly complete normalization of
the majority of diabetes-induced changes (Rescued and
Prevented categories) by insulin treatment points to
their regulation by insulin signalling and/or hyperglyce-
mia. Expression of genes in the Not Rescued category
was not correlated to blood glucose or glycosylated
hemoglobin and first occur after just one month of dia-
betes and before we have observed changes in retinal
vascular permeability or apoptosis [14]. This indicates
that the dysregulation of these genes is most likely not
due to irreversible tissue damage. Previous reports sug-
gest that many of the genes observed to be treatment
resistant are localized to Müller, endothelial, and neuro-
nal cell populations. While further studies are necessary
to localize these changes to specific cell types, these
results suggest that the observed changes are not the
result of deposited leukocytes. An alternate mechanism
for the un-responsiveness of these genes may be
through epigenetic mechanisms such as altered chroma-
tin status or differential DNA methylation of promoter
r e g i o n s[ 3 7 , 5 4 ] .G e n e si nt h eN o tP r e v e n t e da n dP a r -
tially Prevented groupings are unchanged at 1 month of
u n c o n t r o l l e dd i a b e t e sb u ta r ed y s r e g u l a t e da tt h r e e
months of diabetes despite blood glucose control for the
prior 1.5 months. These dysregulations may occur,
despite insulin therapy, as a secondary effect of the
genes not rescued with insulin or due to the non-phy-
siologically regulated release of insulin in these rats.
Future studies will need to examine the effects of
intensive insulin therapy or beta cell transplantation on
normalization of retinal gene expression. Ultimately,
protein expression studies and localization of changes to
specific cellular populations will help provide the neces-
sary distinction between adaptive and pathological
changes. We have already characterized a small number
of insulin therapy resistant changes in retinal protein
expression with diabetes [18] and these transcriptomic
findings suggest that the quantitative proteomic analysis
of retinal protein expression not normalized by insulin
treatment is warranted. Individually, the genes discov-
ered in this study to be not normalized by insulin treat-
ment are targets for functional analyses using genetic
and pharmacological approaches. Drug discovery efforts
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Page 11 of 14that target diabetes-related molecular alterations that are
not normalized by insulin are needed to develop an
adjuvant therapy that, in conjunction with insulin repla-
cement, restores retinal gene expression and tissue func-
tion to a healthy state.
Conclusions
The goal of the current study was to identify molecular
alterations induced in the retina with diabetes that are
not normalized by chronic insulin treatment, using a
well-characterized rodent model of insulin-dependent
diabetes. Transcriptomic analysis and extensive targeted
confirmations demonstrated that, although insulin nor-
malizes expression of the majority of genes altered after
three months of untreated diabetes, expression of a
number of genes remain partially or totally not normal-
ized following therapy. This work demonstrated 1) that
insulin alone is insufficient to completely return the dia-
betic retinal molecular phenotype to a non-diabetic con-
trol state, and 2) that the limitations of insulin therapy
are manifested as both a failure to reverse some altera-
tions that occur before the initiation of insulin therapy
and an inability to prevent some changes that occur
after the initiation of therapy.
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